Komori
Mochida Pharmaceutical (4534) · InitiativeRestated

Company-wide risk management framework under the Risk Management Rules

First written in FY2019. 6 of 9 entries say "Restated". Latest entry: FY2026.

9entries
8years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2019 – FY2020-Q3AdvancedFY2020RestatedFY2021 – FY2022AdvancedFY2023RestatedFY2025 – FY20262019: 220192020: 220202021: 120212022: 120222023: 120232024: 020242025: 120252026: 12026
Same theme, other companies
Regular Risk Deliberations by the Risk Management CommitteeA theme 149 companies write about · 0 as a headwind · 131 as a tailwind

82 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 149 companies compared. The sentences above are computed from all 149.
Full recordFilings, disclosures and news, newest first
  1. FY2026RestatedAnnual report

    「In addition to establishing Risk Management Regulations applicable to the Group, the Company has established a Risk Management Committee to manage major risks relating to overall business operations, including sustainability-related risks. The committee meets twice a year and is chaired by the executive officer responsible for corporate planning and administration. It deliberates on and oversees preventive measures to prevent each major risk from materializing, and response measures if it does materialize, as formulated by the department or company responsible for the relevant risk.」

    The company reaffirms its system for deliberating on and overseeing major risks, including sustainability-related risks, through the Risk Management Committee, which meets twice a year.
  2. FY2025RestatedAnnual report

    「The Company has established a Risk Management Committee to manage major risks relating to overall business operations, including sustainability-related risks. The committee meets twice a year and is chaired by the executive officer responsible for corporate planning and administration. It deliberates on and oversees preventive measures to prevent each major risk from materializing, and response measures if it does materialize, as formulated by the department or company responsible for the relevant risk.」

    The company reaffirms its system for deliberating on and overseeing preventive and response measures for major risks, including sustainability-related risks, through the Risk Management Committee, which meets twice a year.
  3. FY2023AdvancedAnnual report

    「In addition to establishing Risk Management Regulations applicable to the Group, the Company has established a Risk Management Committee to manage major risks relating to overall business operations, including sustainability-related risks. The committee meets twice a year and is chaired by the executive officer responsible for corporate planning and administration. It deliberates on and oversees preventive measures to prevent each major risk from materializing, and response measures if it does materialize, as formulated by the department or company responsible for the relevant risk.」

    The company has detailed its existing company-wide risk management system, including the frequency of Risk Management Committee meetings, deliberation on preventive and response measures, and reporting to the Board of Directors, including for sustainability-related risks.
  4. FY2022RestatedAnnual report

    「In addition to establishing Risk Management Regulations applicable to the Group, the Company has established a Risk Management Committee comprising the heads of each division and presidents of subsidiaries, among others, and identifies and evaluates risks that could have a material adverse impact (loss) on the Group’s business and management, as well as examining and monitoring countermeasures at the company-wide level.」

    The company continues its company-wide identification and evaluation of major risks and examination of countermeasures through the Risk Management Regulations and the Risk Management Committee.
  5. FY2021RestatedAnnual report

    「In addition to establishing Risk Management Regulations applicable to the Group, the Company has established a Risk Management Committee comprising the heads of each division and presidents of subsidiaries, among others, and identifies and evaluates risks that could have a material adverse impact (loss) on the Group’s business and management, as well as examining and monitoring countermeasures at the company-wide level.」

    The company continues to identify and evaluate major risks and examine countermeasures through the Risk Management Regulations and the Risk Management Committee.
  6. FY2020AdvancedAnnual report

    「In addition to establishing Risk Management Regulations applicable to the Group, the Company has established a Risk Management Committee comprising the heads of each division and presidents of subsidiaries, among others, and identifies and evaluates risks that could have a material adverse impact (loss) on the Group’s business and management, as well as examining and monitoring countermeasures at the company-wide level.」

    In addition to the existing Risk Management Regulations, the company has detailed the establishment of a Risk Management Committee comprising the heads of each division and presidents of subsidiaries, among others, and the company-wide identification and evaluation of major risks and examination of countermeasures.
  7. FY2020-Q3RestatedAnnual report

    「Specifically, as part of the internal control system required under the Companies Act, the Company has established a system for managing major risks relating to overall business operations, including a company-wide risk management system under the Mochida Pharmaceutical Group Risk Management Regulations.」

    The company reaffirms its policy of maintaining a company-wide risk management system under the Risk Management Regulations to manage major risks relating to overall business operations.
  8. FY2020-Q2RestatedAnnual report

    「Specifically, as part of the internal control system required under the Companies Act, the Company has established a system for managing major risks relating to overall business operations, including a company-wide risk management system under the Mochida Pharmaceutical Group Risk Management Regulations.」

    The company reaffirms its policy of maintaining a company-wide risk management system under the Risk Management Regulations to manage major risks relating to overall business operations.
  9. FY2019First statedAnnual report

    「The Company has established a system for managing major risks relating to overall business operations, including a company-wide risk management system under the Mochida Pharmaceutical Group Risk Management Regulations.」

    The company discloses for the first time a company-wide system for managing major risks across its overall business operations under the Risk Management Regulations.
Moved together

"Partnerships that connect internal and external resources" moved the same way as this thread, in the same document, in 2 of its 9 moves.

22222★12345
  1. ★This thread
  2. 1Partnerships that connect internal and external resources2×
  3. 2Lifecycle Management and Strategic Alliances2×
  4. 3Progress in Regulatory Approvals, Applications, and Clinical Development2×
  5. 4Expansion of the Dermatology-Based Skincare Business2×
  6. 5Balance Between Retained Earnings and Shareholder Returns2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Mochida Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Company-wide risk management framework under the Risk Management Rules | Mochida Pharmaceutical Co.,Ltd. (4534) | Komori